Theravance Biopharma (TBPH) Finished Goods (2013 - 2018)

Theravance Biopharma (TBPH) has 6 years of Finished Goods data on file, last reported at $3.5 million in Q3 2018.

• On a quarterly basis, Finished Goods fell 22.92% year-over-year to $3.5 million in Q3 2018; TTM through Sep 2018 was $3.5 million, a 22.92% decrease from a year earlier, with the FY2017 full-year figure at $5.0 million, up 42.8% from the prior year.
• Finished Goods for Q3 2018 stood at $3.5 million, down from $4.0 million in the prior quarter.
• Over the last five years, Finished Goods for TBPH reached as high as $7.5 million in Q3 2014 and fell as low as $2.0 million in Q2 2017.
• Historically, Finished Goods has averaged $4.3 million across 5 years, with a median of $4.6 million in 2017.
• Across the five-year window, Finished Goods plunged 58.75% in 2016 and jumped 99.6% in 2018, its largest moves.
• Year by year, Finished Goods stood at $5.6 million in 2014, then slumped by 43.71% to $3.1 million in 2015, then increased by 12.44% to $3.5 million in 2016, then jumped by 42.8% to $5.0 million in 2017, then sank by 30.29% to $3.5 million in 2018.
• Per Business Quant data, the three most recent Finished Goods figures were $3.5 million in Q3 2018, $4.0 million in Q2 2018, and $4.6 million in Q1 2018.